Biogen Idec
Biogen Idec is an American biotechnology company that delivers therapies for the treatment of neurodegenerative diseases, haemophilia and autoimmune disorder.
Founded in 1978, Biogen Idec is an American independent biotechnology company. Biogen combines science and medicine to discover, develop and deliver therapies for the treatment of neurodegenerative diseases, haemophilia and autoimmune disorder.
Biogen is partners with Swedish Orphan Biovitrum ( Sobi) in the development and commercialization of Eloctate, a drug used to treat hemophilia A. Biogen anticipates Eloctate to market in mid-2014.
Latest Biogen Idec News & Features
28 June 2024
19 June 2024
10 June 2024
6 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze